(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 November 2021 (18.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/231646 A1

(51) International Patent Classification:
A61K 31/185 (2006.01) *A61K 45/06* (2006.01)
A61K 31/19 (2006.01) *C07J 9/00* (2006.01)
A61K 31/192 (2006.01)

(21) International Application Number:
PCT/US2021/032085

(22) International Filing Date:
12 May 2021 (12.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/024,360 13 May 2020 (13.05.2020) US

(71) Applicant: **TERNS PHARMACEUTICALS, INC.** [US/US]; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US).

(72) Inventors: **FENAUX, Martijn**; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **KLUCHER, Kevin**; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **JONES, Christopher T.**; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US). **KIRSCHBERG, Thorsten A.**; 1065 E. Hillsdale Blvd., Suite 100, Foster City, California 94404 (US).

(74) Agent: **REANEY, Shannon**; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMBINATION TREATMENT OF LIVER DISORDERS




FIG. 20

(1) 3 mpk Compound 1
(2) 1 mpk Compound 2
(3) 3 mpk Compound 1 + 1 mpk Compound 2

(57) Abstract: Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and a THKβ agonist.

[Continued on next page]

WO 2021/231646 A1

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*